We are focusing on the development of treatments for neuromuscular and neuro-ophthalmological diseases that currently lack treatment options, such as Leber's hereditary optic neuropathy (LHON), Duchenne muscular dystrophy (DMD), congenital muscular dystrophy (CMD) and primary progressive multiple sclerosis (PPMS).
We have dedicated more than a decade to researching potential treatments in our ongoing mission to make effective medicines available for these often overlooked, life-altering diseases. We are passionate about improving patients’ quality of life and are well on the way to becoming leaders in rare mitochondrial and neuromuscular disorders.
Santhera Pharmaceuticals was founded in September 2004 through the merger of two start-up biotech companies, MyoContract AG (Switzerland) and Graffinity Pharmaceuticals AG (Germany).
Santhera’s headquarters are located in Liestal, Switzerland (near Basel), with subsidiaries in Germany, the UK, Italy, the Netherlands, Liechtenstein, the US and Canada.
Santhera’s shares have been listed on the SIX Swiss Exchange under the ticker “SANN” since November 2006.
From the beginning, we have been committed to helping patients through the discovery, development and commercialization of medicines. Since 2004, we have developed our pipeline by conducting numerous clinical studies in Europe and North America.
In September 2015, we received our first approval, the European Marketing Authorization, for Raxone in the treatment of patients with LHON. This makes Raxone the first and only medicine to be approved for this condition. Indeed, it is the first to be approved for any mitochondrial disorder: a major milestone in addressing the unmet medical need represented by this group of rare diseases.